Edwards Lifesciences Corp. Earnings

Edwards Lifesciences Corp.’s revenue fell -11.61% since last year same period to $1412.7Mn in the Q1 2025. On a quarterly growth basis, Edwards Lifesciences Corp. has generated 1.94% jump in its revenue since last 3-months.

Edwards Lifesciences Corp.’s net profit jumped 1.73% since last year same period to $358Mn in the Q1 2025. On a quarterly growth basis, Edwards Lifesciences Corp. has generated -7.16% fall in its net profits since last 3-months.

Edwards Lifesciences Corp.’s net profit margin jumped 15.09% since last year same period to 25.34% in the Q1 2025. On a quarterly growth basis, Edwards Lifesciences Corp. has generated -8.93% fall in its net profit margins since last 3-months.

Edwards Lifesciences Corp.’s price-to-earnings ratio after this Q1 2025 earnings stands at 30.51.

Edwards Lifesciences Corp.’s earning per share (EPS) estimates for the current quarter stand at 0.6 - a 7.39% jump from last quarter’s estimates.

Edwards Lifesciences Corp.’s earning per share (EPS) estimates for the current year stand at 0.6.

Edwards Lifesciences Corp.’s earning per share (EPS) fell -3.03% since last year same period to 0.64 in the Q1 2025. This indicates that the Edwards Lifesciences Corp. has generated -3.03% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Edwards Lifesciences Corp.’s return on assets (ROA) stands at 0.08.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Edwards Lifesciences Corp.’s return on equity (ROE) stands at 0.17.